scPharmaceuticals Stock (NASDAQ:SCPH), Trade Ideas

scPharmaceuticals

scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.

Penny Stocks

Short Ideas

Health Care

Small Cap

Trading Ideas

General

NVAX

NVTA

OMER

SAVA

SCPH

STOK

TARS

TLRY

As of the close of business on Wednesday, 6/28, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector.

The average short interest for stocks within the Healthcare sector stands at 3.48%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.

Short Interest Sector Focus: Healthcare Sector

BDTX

SENS

As of the close of business on Tuesday, 6/27, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector.

The average short interest for stocks within the Healthcare sector stands at 3.51%. Therefore, the below stocks are showing a more pessimistic outlook than their peers within the respective sector.

Earnings

News

Eurozone

Commodities

Global

Intraday Update

Markets

AZYO

CDTX

SOPA

VNET

ZFOX

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Thursday.

The Dow traded up 0.47% to 32,180.26 while the NASDAQ rose 1.29% to 11,820.77. The S&amp;P 500, also rose, gaining, 0.67% to 3,963.50.

Dow Up 150 Points; Gold Jumps Over 2%

scPharmaceuticals Inc

Management

AFJK

On April 15, Aimei Health Technology's Juan Fernandez Pascual Tendered His Resignation As CEO, Secretary And A Director; Co Appointed Junheng Xie As CEO, Secretary And A Director

Honda Exec Says Company To Invest 4.2B Reais In Brazil Plant, Focusing On Hybrid-Flex Vehicles

COSM

Cosmos Health Received Nasdaq Notice On Late Filing Of Its Form 10-K; On April 17 Received Notification Letter Stating Co Is No Longer In Compliance With Nasdaq Listing Rule 5250(c)(1); Intends To Resolve Deficiency And Regain Compliance With Nasdaq Listing Rules

BTOG

On Feb 19, Bit Origin Ltd Terminated Employment Of Its CFO, Xia Wang; On April 10, Lucas Wang Resigned As CEO And Chairman Of Board; Current COO, Has Been Appointed CEO, Chairman Of Board And A Director Of Co; Co To Conduct A Search To Replace Xia Wang As Company's CFO

Whales with a lot of money to spend have taken a noticeably bearish stance on ServiceNow.
Looking at options history for ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) we detected 56 trades.
If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 64% with bearish.
From the overall spotted trades, 25 are puts, for a total amount of $1,473,153 and 31, calls, for a total amount of $2,469,435.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $300.0 to $1040.0 for ServiceNow over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ServiceNow's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ServiceNow's whale trades within a strike price range from $300.0 to $1040.0 in the last 30 days. 
<h3>ServiceNow Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713559550_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$108.8</td>
<td>$106.7</td>
<td>$108.8</td>
<td>$700.00</td>
<td>$598.4K</td>
<td style="text-align: right;">142</td>
<td style="text-align: right;">56</td>
</tr>
<tr>
<td>NOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$37.0</td>
<td>$31.7</td>
<td>$36.5</td>
<td>$500.00</td>
<td>$310.2K</td>
<td style="text-align: right;">35</td>
<td style="text-align: right;">85</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$39.1</td>
<td>$36.7</td>
<td>$39.1</td>
<td>$700.00</td>
<td>$293.2K</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">75</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$32.8</td>
<td>$32.1</td>
<td>$32.1</td>
<td>$720.00</td>
<td>$227.9K</td>
<td style="text-align: right;">75</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$33.0</td>
<td>$31.9</td>
<td>$33.0</td>
<td>$800.00</td>
<td>$132.0K</td>
<td style="text-align: right;">131</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h3>About ServiceNow</h3>
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.
<h3>Current Position of ServiceNow</h3>
<ul>
<li>Trading volume stands at 1,536,830, with NOW's price down by -2.39%, positioned at $713.91.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for ServiceNow, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

This Is What Whales Are Betting On ServiceNow

Financial giants have made a conspicuous bearish move on AstraZeneca. Our analysis of options history for AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) revealed 12 unusual trades.
Delving into the details, we found 16% of traders were bullish, while 83% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $90,336, and 9 were calls, valued at $981,928.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $66.0 and $77.5 for AstraZeneca, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for AstraZeneca's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AstraZeneca's whale activity within a strike price range from $66.0 to $77.5 in the last 30 days. 
<h3>AstraZeneca Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713559545_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.06</td>
<td>$0.9</td>
<td>$0.9</td>
<td>$67.50</td>
<td>$594.6K</td>
<td>14.1K</td>
<td>8.2K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.65</td>
<td>$1.54</td>
<td>$1.55</td>
<td>$67.00</td>
<td>$69.4K</td>
<td>2.5K</td>
<td>2.3K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.52</td>
<td>$1.51</td>
<td>$1.51</td>
<td>$67.00</td>
<td>$67.6K</td>
<td>2.5K</td>
<td>1.0K</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/19/24</td>
<td>$1.49</td>
<td>$1.25</td>
<td>$1.49</td>
<td>$67.00</td>
<td>$66.7K</td>
<td>2.5K</td>
<td>24</td>
</tr>
<tr>
<td>AZN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$1.57</td>
<td>$1.48</td>
<td>$1.49</td>
<td>$67.00</td>
<td>$49.6K</td>
<td>2.5K</td>
<td>920</td>
</tr>
</tbody>
</table>

<h3>About AstraZeneca</h3>
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
Following our analysis of the options activities associated with AstraZeneca, we pivot to a closer look at the company's own performance.
<h3>Where Is AstraZeneca Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,720,283, the price of AZN is up by 0.28%, reaching $68.55.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 6 days from now.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest AstraZeneca options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Looking At AstraZeneca's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bearish stance on Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALAB, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Astera Labs.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 55%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $55,500, and 8, calls, for a total amount of $413,781.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $35.0 to $100.0 for Astera Labs during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Astera Labs's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Astera Labs's whale trades within a strike price range from $35.0 to $100.0 in the last 30 days. 
<h3>Astera Labs Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713559539_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$21.0</td>
<td>$20.0</td>
<td>$21.0</td>
<td>$50.00</td>
<td>$73.5K</td>
<td style="text-align: right;">43</td>
<td style="text-align: right;">39</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$32.7</td>
<td>$30.9</td>
<td>$32.52</td>
<td>$35.00</td>
<td>$65.0K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$7.7</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$65.00</td>
<td>$63.8K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">89</td>
</tr>
<tr>
<td>ALAB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$6.1</td>
<td>$5.6</td>
<td>$5.9</td>
<td>$65.00</td>
<td>$59.0K</td>
<td style="text-align: right;">37</td>
<td style="text-align: right;">472</td>
</tr>
<tr>
<td>ALAB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$11.1</td>
<td>$10.7</td>
<td>$11.1</td>
<td>$75.00</td>
<td>$55.5K</td>
<td style="text-align: right;">425</td>
<td style="text-align: right;">66</td>
</tr>
</tbody>
</table>

<h3>About Astera Labs</h3>
Astera Labs Inc is a company that offers an Intelligent Connectivity Platform, comprised of Semiconductor-based, high-speed mixed-signal connectivity products that integrate a matrix of microcontrollers and sensors. COSMOS, their software suite which is embedded in its connectivity products and integrated into their customers' systems. The Company delivers critical connectivity performance, enables flexibility and customization, and supports observability and predictive analytics. This approach addresses the data, network, and memory bottlenecks, scalability, and other infrastructure requirements of hyperscalers and system original equipment manufacturers.
Having examined the options trading patterns of Astera Labs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Astera Labs</h3>
<ul>
<li>Trading volume stands at 3,996,863, with ALAB's price down by -10.18%, positioned at $63.7.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
<h3>What Analysts Are Saying About Astera Labs</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $88.0.
<ul>
<li>Reflecting concerns, an analyst from Evercore ISI Group lowers its rating to Outperform with a new price target of $100.</li>
<li>An analyst from Barclays downgraded its action to Overweight with a price target of $85. </li>
<li>Reflecting concerns, an analyst from Roth MKM lowers its rating to Buy with a new price target of $85.</li>
<li>In a cautious move, an analyst from JP Morgan downgraded its rating to Overweight, setting a price target of $85. </li>
<li>Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $85.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Astera Labs, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ALAB

Decoding Astera Labs's Options Activity: What's the Big Picture?

GILD

LPTX

Leap Therapeutics 13G Filing Shows Gilead Sciences, Inc. Reported A 13.9% Stake In The Co As Of April 10, 2024

Offerings

KZIA

Kazia Therapeutics Ltd Entered Into Purchase Agreement With Alumni Capital LP; Pursuant To Purchase Agreement, May Sell To Alumni Capital Up To $15M Of American Depositary Shares From Time To Time

MNTS

Momentus Inc Receives Nasdaq Deficiency Notification Regarding Delayed Form 10-K

Gulf Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GURE#NASDAQ">GURE</a>) ("Gulf Resources" or the "Company"), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today announced that it received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that due to the Company's failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the "2023 Form 10-K"), with the Securities and Exchange Commission (the "SEC"), the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires the timely filing of all required periodic reports with the SEC. &nbsp;
The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. Under the Nasdaq rules, the Company has 60 calendar days, or until June 17, 2024, to file the 2023 Form 10-K or to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If the Company submits a plan to Nasdaq and Nasdaq accepts the plan, Nasdaq can grant an exception of up to 180 calendar days from the filing's due date, or until October 14, 2024, to regain compliance. If the Company fails to timely regain compliance with Nasdaq Listing Rule 5250(c)(1), the Company's common stock will be subject to delisting from Nasdaq.
The Company continues to work diligently to complete the 2023 Form 10-K and currently intends to file the 2023 Form 10-K by no later than June 10, 2024.
This announcement is made in compliance with the Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a notification of deficiency.

GURE

Gulf Resources Announces Receipt Of Nasdaq Non-Compliance Notice Notifying The Company That Due To The Co's Failure To Timely File Its Annual Report On Form 10-K For The Fiscal Year Ended December 31, 2023

Lifecore Biomedical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFCR#NASDAQ">LFCR</a>) (the "Company") announced today that, on April 15, 2024, the Company received a notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the "Q3 Form 10-Q") and its continued delay in filing its Quarterly Report on Form 10-Q for the quarterly periods ended August 27, 2023 and November 29, 2023 (the "Q1 Form 10-Q" and "Q2 Form 10-Q," respectively, and together with the Q3 Form 10-Q, the "Filings") with the Securities and Exchange Commission (the "SEC"), the Company continues not to be in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), and that the Nasdaq Hearings Panel would consider the delinquency in the filing of the Q3 Form 10-Q in rendering its determination regarding the Company's continued listing on Nasdaq Global Select Market. &nbsp;
The Notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Global Select Market. As previously disclosed, Nasdaq had previously granted the Company until February 12, 2024 to regain compliance with the Listing Rule, and, on February 13, 2024, the Company received the Staff Delisting Determination notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company's securities from Nasdaq as a result of the Company not being in compliance with the Listing Rule. The Company appealed the Staff Delisting Determination, and, on April 16, 2024, the Company appeared for the hearing in which the Company requested a further stay of any suspension or delisting action to enable the Company to regain compliance with the Listing Rule. The Nasdaq Hearings Panel has not yet issued its decision, although the Company anticipates that a decision will be forthcoming.
The Company continues to work diligently to complete the Filings and intends to file the Filings as promptly as possible to regain compliance under the Listing Rule. However, there can be no assurance that such periodic reports will be filed before the expiration of any stay granted by Nasdaq, or that the Nasdaq Hearing Panel will grant the Company's request for a further stay of any suspension or delisting action
This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

LFCR

Lifecore Biomedical, Inc. Receives Notice From Nasdaq Regarding Delayed Quarterly Report For The Fiscal Quarter Ended February 25, 2024 And Its Continued Delay In Filing Its Quarterly Report On Form 10-Q For The Quarterly Periods Ended August 27, 2023 And November 29, 2023

Odyssey Marine Exploration, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>), a global subsea mineral exploration and validation company, reported that on April 17, 2024, Odyssey received a notice from Nasdaq Regulation that Odyssey is not in compliance with Nasdaq Rule 5250(c)(1) because it had not yet filed its Form 10-K for the period ended December 31, 2023 (the "Form 10-K") with the Securities and Exchange Commission (SEC). Odyssey plans to regain compliance with Nasdaq Rule 5250(c)(1) by filing the Form 10-K with the SEC, which it expects to do as soon as practicable.

OMEX

Odyssey Marine Exploration Addresses NASDAQ Compliance Matters; Plans To Regain Compliance With Nasdaq Rule 5250(c)(1) By Filing The Form 10-K With The SEC, Which It Expects To Do As Soon As Practicable

Intelligent Living Application Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) ("Intelligent Living" or the "Company"), a premium lockset manufacturer in Hong Kong, announced today that, on April 17, 2024, the Company received a written notification from the NASDAQ Stock Market Listing Qualifications Staff (the "Staff") indicating that the Company has been granted an additional 180 calendar day period or until October 14, 2024, to regain compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital Market pursuant to NASDAQ Listing Rule (the "Minimum Bid Price Requirement").
NASDAQ's determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the NASDAQ Capital Market, with the exception of the bid price requirement, and the Company's written notice to NASDAQ of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time during this additional time period the closing bid price of the Company's security is at least $1.00 per share for a minimum of 10 consecutive business days, NASDAQ will provide written confirmation of compliance and this matter will be closed. If compliance cannot be demonstrated by October 14, 2024, Staff will provide written notification that the Company's securities will be delisted. At that time, the Company may appeal the Staff's determination to a Hearings Panel (the "Panel") of NASDAQ.
This notification from Nasdaq has no immediate effect on the listing or trading of the Company's ordinary shares, which will continue to trade on the Nasdaq Capital Market under the symbol "ILAG".&nbsp; The Company will monitor the closing bid price of its ordinary shares and will consider various options to regain compliance before October 14, 2024.

ILAG

Intelligent Living Application Group Inc. Granted Extension Indicating That The Co Has Been Granted An Additional 180 Day Or Until October 14, 2024, To Regain Compliance With The $1.00 Minimum Closing Bid Price Requirement To Meet Nasdaq Minimum Bid Price Requirement

ReAlpha Tech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) reported quarterly losses of $(0.03) per share. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The company reported $20.43 thousand in sales this quarter. This is a 81.67 percent decrease over sales of $111.45 thousand the same period last year.

AIRE

ReAlpha Tech Corp Q1 EPS $(0.03) Down From $(0.02) YoY, Sales $20.43K Down From $111.45K YoY

Editor&#8217;s Note: This article has been updated with additional details.
Howard Marks, co-chairman of Oaktree Capital Management, frequently employs analogies to demystify <a href="https://www.benzinga.com/topic/investing">complex investment strategies</a>, believing that &#8220;Oftentimes, we're best able to understand something we're interested in through analogies that clarify the matter by establishing connections between it and other parts of life.&#8221; 
His latest <a href="https://www.oaktreecapital.com/insights/memo/the-indispensability-of-risk">memo </a>draws from a compelling chess article, underscoring the strategic similarities between the game and investing.
Marks cites the article &#8220;Chess Teaches the Power of Sacrifice,&#8221; which resonated with him due to its discussion on strategic sacrifices necessary in chess — a concept he equates to making investment decisions. 
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38339754/netflix-stock-sized-up-by-7-analysts-post-q1-results-pivot-from-a-high-growth-low-p">Netflix Stock Sized Up By 7 Analysts Post Q1 Results: &#8216;Pivot From A High-Growth, Low-Profit Business To A Slow-Growth, High-Profit Business&#8217;</a>
Marks quotes chess grandmaster Maurice Ashley, &#8220;Many positions cannot be won or saved without something of value being given away, from a lowly pawn all the way up to the mighty queen,&#8221; to highlight that strategic losses in chess mirror the sacrifices made in high-stakes investing.
He relates this to buying U.S. Treasury notes, describing them as a &#8220;modest or &#8216;sham&#8217; sacrifice,&#8221; where the risk is low but so are the returns.
The philosophy of risk is central to Marks&#8217; investment strategy. He emphasizes, &#8220;No risk, no reward,&#8221; a principle vital in chess and financial markets. 
Marks also incorporates the wisdom of five-time world chess champion Magnus Carlsen, asserting, &#8220;Not being willing to take risks is an extremely risky strategy.&#8221; 
This idea supports Marks&#8217; view that managing risk intelligently is crucial for achieving substantial returns. Quoting Kenny "The Jet" Smith, he adds, &#8220;You have to give yourself a chance to fail,&#8221; underlining the inevitability of risk in pursuit of success.
Marks also highlighted the strategy behind Berkshire Hathaway&#8217;s achievements, led by Warren Buffett and Charlie Munger: &#8220;a lot of investments in which they did decently, a relatively small number of big winners that they invested in heavily and held for decades, and relatively few big losers.&#8221; 
This approach underscores the importance of a balanced portfolio over chasing perpetual high performers.
Marks concludes by reflecting on the broader implications of risk, stating, &#8220;The only sure way to achieve that is by not taking any risk. But … risk avoidance is likely to result in return avoidance.&#8221; 
Now Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38339548/exclusive-industry-leaders-predict-how-the-bitcoin-halving-impacts-prices-and-mining">EXCLUSIVE: Industry Leaders Predict How The Bitcoin Halving Impacts Prices And Mining</a>
Image generated using artificial intelligence via Midjourney.

Education

Personal Finance

Billionaire Credit Investor Unveils Warren Buffett's Strategy As Part Of Why He Takes Risks (UPDATED)

Cryptocurrency markets surged on Friday, with a 47.5% spike in total crypto liquidations reaching $258.7 million and a more than double increase in total exchange inflows, as investors eagerly await the <a href="https://www.benzinga.com/topic/bitcoin-halving">Bitcoin Halving</a> set to occur in a few hours. 
What Happened: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38334504/israel-strikes-iranian-air-base-tehran-downplays-attack-as-blinken-calls-for-calm-oil-pric">Geopolitical tensions</a> continue to weigh on global markets, including stocks and crypto, following Israel&#8217;s military strike on Iran in the early hours of Friday.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Gains +/-</td>
<td>Price</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>+1.0%</td>
<td>$64,161.87</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>+0.8%</td>
<td>$3,094.50</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>+1.7%</td>
<td>$0.1535</td>
</tr>
</tbody>
</table>
</figure>
The global cryptocurrency market cap now stands at 2.35 trillion, up 4.7% in the past 24 hours. In the same period, 84,226 traders were liquidated, with total liquidations amounting to $257.93 million. The largest single liquidation order took place on OKX &#8211; ETH-USD-SWAP, valued at $5.03 million. Bitcoin liquidations in the past 24 hours are nearing the 100 million mark, with long liquidations at $52 million and short liquidations at $44.6 million.
Top Gainers
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Gains +/-</td>
<td>Price</td>
</tr>
<tr>
<td>Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>)</td>
<td>+15.4%</td>
<td>$2.97</td>
</tr>
<tr>
<td>THORChain (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/rune/usd">RUNE</a>)</td>
<td>+12.3%</td>
<td>$5.45</td>
</tr>
<tr>
<td>Internet Computer Protocol (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ICP</a>)</td>
<td>+11.7%</td>
<td>$14.13</td>
</tr>
</tbody>
</table>
</figure>
IntoTheBlock data highlights that 91% of Bitcoin holders are currently in profit, while 9% are at breakeven. Total exchange inflows more than doubled to 2.54 billion as of April 18 from 1.1 billion on April 17, and daily active addresses increased by 4.3% to 828,630.
Analyst Notes: Paxton, the creator of Binance Square, tweeted that Bitcoin is in a significant rally.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> might surprise us after the halving with a quick dip to gather more fuel for its climb!<a href="https://twitter.com/hashtag/BTC?src=hash&amp;ref_src=twsrc%5Etfw">#BTC</a> <a href="https://twitter.com/hashtag/halving?src=hash&amp;ref_src=twsrc%5Etfw">#halving</a> <a href="https://twitter.com/hashtag/Binance?src=hash&amp;ref_src=twsrc%5Etfw">#Binance</a> <a href="https://t.co/kbkiuBuZUx">pic.twitter.com/kbkiuBuZUx</a>
&mdash; Paxton (@Buy_SomeBTC) <a href="https://twitter.com/Buy_SomeBTC/status/1781370980444545398?ref_src=twsrc%5Etfw">April 19, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, notable crypto trader and analyst CrediBULL Crypto hinted at a potential upward grind despite a momentum stall in his latest <a href="https://twitter.com/CredibleCrypto/status/1781393488145490205">X</a> post. 
He noted that while Bitcoin&#8217;s momentum had stalled overnight, resulting in a three-legged move instead of a clean five-wave impulse, the cryptocurrency could still see an upward trend. However, he cautioned market participants to remain vigilant and consider potential risks when reaching range highs.
What's Next: The influence of <a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a> is expected to be thoroughly explored at Benzinga's upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38279616/bitcoin-and-ethereum-take-center-stage-according-to-coinbase-q2-crypto-market-guide">Bitcoin And Ethereum Take Center Stage According To Coinbase Q2 Crypto Market Guide</a>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

$ETH

$ICP

$RUNE

$WIF

Bitcoin, Ethereum, Dogecoin Pick Up Steam: The Pre-Halving Week In Retrospect

ATIF

On April 16, ATIF Holdings Ltd Entered Into Securities Purchase Deal, To Sell 1.1M Newly Issued Ordinary Shares Of Co At Price Of $1.23 Per Share

Hepion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives, as previously announced in December 2023. &nbsp;
ASCEND-NASH is a Phase 2b, randomized, multi-center, double-blinded study with first patient screened in August 2022, to evaluate the safety and efficacy of rencofilstat dosed for 12 months, with a target enrollment of 336 subjects. Enrollment was paused in April 2023, with 151 subjects randomized. To date, approximately 80 subjects have completed their Day 365 visits and are evaluable for both safety and efficacy. An additional 40 subjects will provide significant safety data for evaluation. These patients will be added to our existing safety database.
"We are disappointed to announce the wind-down of our Phase 2 NASH trial, which we attribute entirely to resource constraints," said John Brancaccio, Executive Chairman of Hepion. "The Company remains committed to its strategic alternative efforts previously announced in December 2023. Given the number of enrolled NASH patients to date and the low probability of generating relevant efficacy data to support a registrational trial with our current cash resources, we have opted to wind down the program and assure that patients are transitioned out of the trial in a safe and compliant manner. There were no safety concerns observed for rencofilstat in the ASCEND-NASH trial."

Biotech

HEPA

Hepion Pharmaceuticals Initiates Wind-Down Activities In Phase 2b 'ASCEND-NASH' Trial

Six months after Microsoft Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) acquisition of Activision Blizzard, Holly Longdale, executive producer and vice president at World of Warcraft, provided insights into the <a href="https://www.benzinga.com/general/gaming/24/04/38150420/good-news-for-gamers-xboxs-sarah-bond-commits-to-game-preservation-creates-dedicated-team-for-futu">post-acquisition environment. </a>
In an<a href="https://www.videogameschronicle.com/news/microsoft-has-let-blizzard-be-blizzard-following-its-acquisition-studio-says/"> interview </a>with Video Games Chronicle, Longdale revealed Microsoft has largely allowed Blizzard to maintain its autonomy: &#8220;There's no one asking us to do anything.&#8221;
See Also: <a href="https://www.benzinga.com/24/04/38189985/china-welcomes-back-world-of-warcraft-as-blizzard-netease-reach-agreement">China Welcomes Back World Of Warcraft As Blizzard, NetEase Reach Agreement</a>
&#8220;World of Warcraft is doing very well and they're very proud of what it's been able to accomplish, so it's almost like just let it be, and let it keep being awesome,&#8221; the executive added. &#8220;They've been tremendously supportive and it's like ‘let Blizzard be Blizzard.'&#8221;
Longdale also highlighted the benefits of being part of the Microsoft family, mentioning opportunities for communication and information sharing with other Microsoft-owned studios. She mentioned interactions with teams from Mojang and Elder Scrolls Online, suggesting that they could learn from each other&#8217;s experiences.
Despite Longdale&#8217;s positive perspective, the acquisition has not been without its challenges. 
Microsoft&#8217;s gaming division, including Activision Blizzard, underwent <a href="https://www.benzinga.com/news/24/01/36783057/microsofts-major-gaming-shake-up-1-900-layoffs-and-leadership-changes-in-post-acquisition-strategy">significant layoffs in January</a>, affecting 1,900 employees and resulting in the cancellation of projects such as Odyssey. 
In related news, Blizzard recently announced the upcoming expansion for World of Warcraft, titled &#8220;World of Warcraft: The War Within.&#8221; Although it may not match the impact of previous expansions, such as Dragonflight, anticipation remains high for its potential.
Read Next: <a href="https://www.benzinga.com/general/gaming/24/01/36682941/microsofts-satya-nadella-activision-gives-us-a-chance-of-being-a-good-publisher-on-sony-nintendo">Microsoft&#8217;s Satya Nadella: Activision Gives Us A Chance Of Being &#8216;A Good Publisher&#8217; On Sony, Nintendo</a>
Photo: <a href="https://www.shutterstock.com/es/g/DailyFX">CryptoFX</a> on Shutterstock.

Gaming

MSFT

Can Blizzard Keep Its Autonomy Post-Microsoft Acquisition? 'No One Asking Us To Do Anything,' Says World Of Warcraft Exec

scPharmaceuticals Q4 2023 Earnings Preview

Notable earnings after Wednesday's close

scPharmaceuticals GAAP EPS of -$0.35 beats by $0.07, revenue of $6.1M beats by $0.33M

scPharmaceuticals files for $200M mixed shelf offering

scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript

TD Cowen analyst Stacy Ku maintained a Buy rating on scPharmaceuticals (SCPH – Research Report) yesterday and set a price target of $25.00. Stacy K...

Strong Buy Recommendation for scPharmaceuticals on Furoscix's Successful Launch and Growth Prospects

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurocrine (NBIX – Research Report), Jazz Pharmace...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)

Naz Rahman, an analyst from Maxim Group, reiterated the Buy rating on scPharmaceuticals (SCPH – Research Report). The associated price target is $2...

Buy Rating Affirmed for scPharmaceuticals Amidst Revenue Surge and Solid Financial Footing

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immuneering (IMRX – Research Report), Structure Ther...

Analysts Are Bullish on These Healthcare Stocks: Immuneering (IMRX), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

ANIK

BGSF

BOXL

CHRS

ECOR

FOSL

FTCI

GORO

GPCR

GRWG

HEAR

HNRG

IMRX

JAZZ

JUSHF

LRFC

NBIX

NVGS

OPTT

PANL

PATH

PFIE

PLNH

PTMN

SPRO

SSSS

Press Releases

scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives

scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

scPharmaceuticals Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update